TD Cowen Increases Price Target for Regeneron Pharmaceuticals Ahead of Fiscal Q1 Results
TD Cowen raised its price target for Regeneron Pharmaceuticals (REGN) to $960 from $880, reaffirming a Buy rating ahead of the company's fiscal Q1 results. The update included adjustments to earnings estimates and the approval of a new gene therapy, Otarmeni, by the FDA.
Tickers: $REGN
Topics: Analyst Upgrade FDA Approval Gene Therapy Regeneron Pharmaceuticals Stock Price Target